Relationships Between Macular Pigment Optical Density and Lacquer Cracks in High Myopic Patients.
NCT ID: NCT02205632
Last Updated: 2018-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
39 participants
INTERVENTIONAL
2014-02-28
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Its absorption peak at 460 nm may reduce photic damages. The macular pigment density can be evaluated by its optical density.
Reduced macular pigment level is a significant risk factor for age-macular degeneration. The nutritional intake can minimise the risk of age-macular degeneration.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation
NCT01404845
Macular Pigment and Glare Disability
NCT00909090
Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients With Age-related Macular Degeneration
NCT00879671
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
NCT01048476
MPOD in Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin
NCT00568828
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High myopic patients with lacker craks
MPS II
High myopic patients without lacker cracks
MPS II
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MPS II
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* High axial myopia \< -6 dioptries
* Presence or not of lacquer cracks in Bruch's membrane in one or both eyes
* Patients with social security coverage
Exclusion Criteria
* Amblyopia in the studied eye
* Prior ocular surgery
* Corneal disease or severe dry eye syndrome
* Other retinal disease: diabetic retinopathy, age-related macular degeneration, macular hole, epiretinal membrane central
* Extensive chorioretinal atrophy
* Allergy to tropicamide
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poitiers University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicolas LEVEZIEL, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Poitiers University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ophthalmology department, Poitiers University Hospital
Poitiers, Vienne, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MPSII-RMB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.